Highlights

  • Second quarter net loss was USD 4,426,578 against USD 5,369,783.
  • Operating expenses fell to USD 4,442,072 from USD 6,271,188.
  • Cash and cash equivalents were USD 3,143,422 at June 30, 2026.
  • The filing states substantial doubt about continuing as a going concern.

GeoVax Labs, Inc. (NASDAQ:GOVX) shares were trading near their all-time low at USD 0.1499 on November 6, 2026, down 5.13% on the day. The company reported a second quarter net loss of USD 4,426,578, or USD 0.97 per share.

Quarter Results

Total operating expenses were USD 4,442,072 against USD 6,271,188, and the loss from operations was USD 4,442,072 against USD 5,418,906. The net loss was USD 4,426,578 against USD 5,369,783, and the loss per share was USD 0.97 against USD 8.74 after retroactive adjustment for the reverse split.

Six-Month Results

Total operating expenses were USD 9,714,953 against USD 13,313,221. The loss from operations was USD 9,714,953 against USD 10,824,076. The net loss was USD 9,688,499, or USD 2.94 per share, against USD 10,727,434, or USD 19.72 per share.

Cash Flow and Balance Sheet

Cash and cash equivalents were USD 3,143,422 against USD 3,085,741 at December 31, 2025. Net cash used in Operating Activities was USD 7,195,824 against USD 10,300,078, and net cash provided by financing activities was USD 7,253,505 against USD 7,914,611.

Total Assets were USD 4,642,757 against USD 6,341,868. Total liabilities were USD 2,882,056 against USD 2,516,736, and total stockholders' Equity was USD 1,760,701 against USD 3,825,132. The accumulated Deficit was USD 160,509,351.

Period-over-Period Balance Sheet Changes

Total assets decreased by USD 1,699,111 from year end, and total stockholders' equity decreased by USD 2,064,431. Total liabilities increased by USD 365,320 over the same period. Cash and cash equivalents rose by USD 57,681 to USD 3,143,422, while net cash used in operating activities for the six months was USD 7,195,824.

Going Concern and Share Count

The filing states that there can be no assurance necessary funding will be available on favorable terms or at all, and that these factors collectively raise substantial doubt about the company's ability to continue as a going concern.

Shares outstanding were 7,369,243 as of June 30, 2026 and July 27, 2026, against 1,732,147 at December 31, 2025. All share and per share information has been retroactively restated for the Reverse Stock Split described in Note 5. Weighted average shares were 4,565,207 in the quarter against 614,369.